Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

PURPOSE: Patients with myelodysplastic syndromes (MDS) often require treatment with growth factors (GFs) or non-GF therapies. One non-GF drug, lenalidomide, is particularly effective at achieving transfusion independence (TI) in patients with lower-risk MDS with the del(5q) cytogenetic abnormality....

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sekeres, Mikkael A., Maciejewski, Jaroslaw P., Giagounidis, Aristotle A.N., Wride, Kenton, Knight, Robert, Raza, Azra, List, Alan F.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2008
Matèries:
Leukemia and Bone Marrow Transplantation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2645116/
https://ncbi.nlm.nih.gov/pubmed/19018091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.15.5770
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars